Skip to main content
Fig. 1 | BMC Cancer

Fig. 1

From: Multicenter Phase II study of FOLFOX or biweekly XELOX and Erbitux (cetuximab) as first-line therapy in patients with wild-type KRAS/BRAF metastatic colorectal cancer: The FLEET study

Fig. 1

Disposition of patients. In all, 139 patients were analyzed for KRAS and BRAF mutation status. Of these, 70 patients (50.4 %) had both KRAS and BRAF wild-type metastatic colorectal cancer, and 62 fulfilled the inclusion criteria for the study. Of the 62 patients enrolled in the study, 37 chose to receive mFOLFOX-6 plus cetuximab treatment (FOLFOX + Cmab), whereas 25 chose XELOX plus cetuximab treatment (XELOX + Cmab)

Back to article page